We have collected information about Sirna Topical Delivery for you. Follow the links to find out details on Sirna Topical Delivery.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4425738/
Apr 10, 2014 · For gene suppression in skin, topical delivery of siRNA offers several benefits including direct access to the target site, reduced adverse effects typically associated with systemic administration, possibility of visual monitoring of the affected region and the possibility of surgical removal of aberrant tissue if unwanted side effects occur ...Author: Ming Chen, Michael Zakrewsky, Vivek Gupta, Aaron C. Anselmo, Deborah H. Slee, John A. Muraski, Samir...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3409786/
Jul 24, 2012 · Topical delivery of 1.5 uM EGFR siRNA (50 nM SNA-NCs) for 3 wk to hairless mouse skin almost completely abolishes EGFR expression, suppresses downstream ERK phosphorylation, and reduces epidermal thickness by almost 40%. Similarly, EGFR mRNA in human skin equivalents is reduced by 52% after 60 h of treatment with 25 nM EGFR SNA-NCs.Author: Dan Zheng, Dan Zheng, David A. Giljohann, David A. Giljohann, David L. Chen, Matthew D. Massich, Mat...
https://www.sciencedirect.com/science/article/pii/S0168365914000236
The nanoparticle systems have shown possibility and efficacy as topical delivery systems for siRNA , , . On the other hand, skin penetrating peptides provide a …Author: Ming Chen, Michael Zakrewsky, Vivek Gupta, Aaron C. Anselmo, Deborah H. Slee, John A. Muraski, Samir...
https://www.researchgate.net/publication/281713077_Progress_in_Topical_siRNA_Delivery_Approaches_for_Skin_Disorders
The topical delivery of siRNA based therapies has opened new perspectives for the treatment of skin disorders. The use of siRNA is limited due to the rapid degradation and poor cellular uptake.
https://www.sciencedirect.com/science/article/pii/S0168365914007202
In vivo gene silencing following non-invasive siRNA delivery into the skin using a novel topical formulation Author links open overlay panel Vikas Hegde a Robyn P. Hickerson a Sitheswaran Nainamalai a 1 Paul A. Campbell a b Frances J.D. Smith a W.H. Irwin McLean a Deena M. Leslie Pedrioli aAuthor: Vikas Hegde, Robyn P. Hickerson, Sitheswaran Nainamalai, Paul A. Campbell, Frances J.D. Smith, W.H. ...
https://www.pnas.org/content/pnas/109/30/11975.full.pdf
knockdown. Therefore, we hypothesized that siRNA-based SNA gold nanoparticle conjugates might be ideal topical delivery agents to treat diseases of the skin. Results To evaluate the potential for targeted gene suppression by siRNA-based SNA-NCs through noninvasive topical delivery, we first investigated their uptake in primary normal human ker-Author: Dan Zheng, Dan Zheng, David A. Giljohann, David A. Giljohann, David L. Chen, Matthew D. Massich, Mat...
https://www.sbir.gov/sbirsearch/detail/400420
This project will seek to improve upon this observation by developing novel topical delivery vehicles that can further penetrate across the tissue within awound. We will examine whether deeper siRNA delivery across a wound correlates with improved wound healing rate and further reduces scar formation in elderly animals and diabetic animal models.
https://www.pnas.org/content/109/30/11975
Jul 24, 2012 · Topical application of nucleic acids offers many potential therapeutic advantages for suppressing genes in the skin, and potentially for systemic gene delivery. However, the epidermal barrier typically precludes entry of gene-suppressing therapy unless the barrier is disrupted. We now show that spherical nucleic acid nanoparticle conjugates (SNA-NCs), gold cores surrounded by a dense shell of ...Author: Dan Zheng, Dan Zheng, David A. Giljohann, David A. Giljohann, David L. Chen, Matthew D. Massich, Mat...
http://www.biopharminternational.com/discovery-pipeline-topical-delivery-sirna
Jul 06, 2012 · A team from Northwestern University has demonstrated the feasibility of topical delivery of small interfering RNA (siRNA) in a July 2012 publication online in the Proceedings of the National Academy of Sciences.To date, the biggest hurdle in developing (siRNA) therapeutics to effect gene knockdown in vivo has been designing an effective delivery system.
https://www.cell.com/molecular-therapy-family/nucleic-acids/pdfExtended/S2162-2531(19)30207-0
Due to the short half-life of siRNA molecules, a daily reversible and dosage-variable treatment regimen by non-invasive topical delivery is necessary. However, effective delivery remains a challenge, and presently no published research reports significant siRNA delivery to an intact corneal epithelium.11,28
Searching for Sirna Topical Delivery?
You can just click the links above. The data is collected for you.
